KEYNOTE-057 in High-Risk, Non-Muscle Invasive Bladder Cancer: Trial Highlights by Tom Keane

December 7, 2018


Tom Keane provides a comprehensive review of phase 2 KEYNOTE-057, assessing treatment with pembrolizumab for high-risk, non-muscle invasive bladder cancer in patients who are unresponsive to Bacillus Calmette (BCG), current standard of care in this patient population.

Biography:

Thomas E. Keane, MBBCh, FRCSI, FACS

email news signup